Comparing Chemotherapy Durations Before Surgery for Pancreatic Cancer

Who can take part

• Borderline or locally advanced pancreatic adenocarcinoma at diagnosis according to NCCN Clinical Practice Guidelines, version 1.2022 • Histo- or cytologically confirmed adenocarcinoma • T1-4, Nx, M0 according to AJCC 8th edition • Age ≥ 18 years-of-age • ECOG 0-1 and considered fit for the planned chemotherapy and surgery • Written informed patient consent

Who cannot take part

• Co-morbidity precluding pancreatic surgery or chemotherapy - Sensitivity to any of the drugs in the proposed management regimens - ECOG ≥2 - neuropathy ≥ grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE), version 6 [47] - granulocyte count < 1500 per cubic millimetre (< 1,5 x 109/L) - platelet count < 100 000 per cubic millimetre (< 100 x 109/L) - serum creatinine > 1.5 UNL (upper limit normal range) - albumin <2,5 g/dl (<25 g/L) - total bilirubin >3 x ULN - ASAT (SGOT) and ALAT (SGPT) >2.5 x institutional ULN - female patients in child-bearing age not using adequate contraception, pregnant or lactating women - mental or somatic disorders which could possibly interfere with informed consent, compliance or the planned treatments - previous oncologic treatment for pancreatic adenocarcinoma within the past 5 years - Any reason according to the investigator why the patient cannot comply with the protocol or is not suitable to participate